DE69324859T2 - Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis - Google Patents
Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider ArthritisInfo
- Publication number
- DE69324859T2 DE69324859T2 DE69324859T DE69324859T DE69324859T2 DE 69324859 T2 DE69324859 T2 DE 69324859T2 DE 69324859 T DE69324859 T DE 69324859T DE 69324859 T DE69324859 T DE 69324859T DE 69324859 T2 DE69324859 T2 DE 69324859T2
- Authority
- DE
- Germany
- Prior art keywords
- lipid
- bound
- glycoaminoglycans
- treatment
- rheumatoid arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20355892A JP3714683B2 (ja) | 1992-07-30 | 1992-07-30 | 抗リウマチ剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69324859D1 DE69324859D1 (de) | 1999-06-17 |
DE69324859T2 true DE69324859T2 (de) | 1999-10-07 |
Family
ID=16476131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69324859T Expired - Fee Related DE69324859T2 (de) | 1992-07-30 | 1993-07-29 | Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis |
Country Status (7)
Country | Link |
---|---|
US (1) | US5470578A (de) |
EP (1) | EP0581282B1 (de) |
JP (1) | JP3714683B2 (de) |
KR (1) | KR940005281A (de) |
AT (1) | ATE179892T1 (de) |
CA (1) | CA2101482A1 (de) |
DE (1) | DE69324859T2 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2232527C (en) * | 1995-09-19 | 2008-09-02 | Seikagaku Corporation | Anti-inflammatory agent |
US5869273A (en) * | 1996-09-13 | 1999-02-09 | Glyko, Inc. | Chondroitin sulfate as a marker of bone resorption |
EP1006183A1 (de) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Rekombinante, lösliche Fc-Rezeptoren |
JP3032824B1 (ja) * | 1999-01-28 | 2000-04-17 | 東京医科歯科大学長 | 骨誘導促進剤 |
US8501701B2 (en) * | 2000-01-10 | 2013-08-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of lipid conjugates in the treatment of disease |
US7608598B2 (en) | 2000-01-10 | 2009-10-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of conjunctivitis |
US9040078B2 (en) | 2000-01-10 | 2015-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases of the nervous system |
US7811999B2 (en) * | 2000-01-10 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
US7772196B2 (en) * | 2000-01-10 | 2010-08-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
US7893226B2 (en) | 2004-09-29 | 2011-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
US8304395B2 (en) * | 2000-01-10 | 2012-11-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lipid conjugates in the treatment of disease |
US20060189570A1 (en) * | 2000-01-10 | 2006-08-24 | Saul Yedgar | Use of lipid conjugates in the treatment of infection |
US8076312B2 (en) | 2000-01-10 | 2011-12-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Use of lipid conjugates in the treatment of disease |
US20090325876A1 (en) * | 2004-09-29 | 2009-12-31 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases associated with vasculature |
US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
WO2001051003A2 (en) * | 2000-01-10 | 2001-07-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
US7101859B2 (en) * | 2000-01-10 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
WO2006054304A2 (en) * | 2004-11-17 | 2006-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
US7393938B2 (en) | 2000-01-10 | 2008-07-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
US8916539B2 (en) * | 2000-01-10 | 2014-12-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
TWI281407B (en) * | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
US8883761B2 (en) * | 2001-01-10 | 2014-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases associated with vasculature |
US20040105883A1 (en) * | 2001-04-17 | 2004-06-03 | Ping Gao | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
US6607745B2 (en) | 2001-05-18 | 2003-08-19 | Harry Leneau | Ingestion of hyaluronic acid for improved joint function and health |
US7635489B2 (en) * | 2001-05-18 | 2009-12-22 | Leneau Holdings, Llc | Ingestion of hyaluronic acid for improved joint health |
CN101653604A (zh) * | 2001-05-30 | 2010-02-24 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
KR20030046810A (ko) * | 2001-12-06 | 2003-06-18 | 은삼제약 주식회사 | 콘드로이친 황산의 분해산물을 포함하는 관절염 예방 또는치료용 약학적 조성물 |
US7211258B2 (en) * | 2002-04-10 | 2007-05-01 | Protalex, Inc. | Protein A compositions and methods of use |
US7425331B2 (en) * | 2002-04-10 | 2008-09-16 | Protalex, Inc. | Protein A methods of use |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
EP1681306B1 (de) * | 2003-10-29 | 2013-02-20 | Teijin Limited | Hyaluronsäureverbindung, hydrogel davon und material zur behandlung von gelenken |
CA2750725C (en) * | 2004-01-07 | 2014-10-21 | Seikagaku Corporation | Spacer derivative for hyaluronic acid and non-steroidal anti-inflammatory drug residues |
EP1740190A1 (de) * | 2004-03-05 | 2007-01-10 | Synthes GmbH | Verwendung eines gemisches für die herstellung eines mittels zur behandlung von defektem oder degeneriertem knorpel in vivo und bei der herstellung von natürlichem knorpelersatz in vitro |
JP4902134B2 (ja) * | 2005-04-25 | 2012-03-21 | 帝人株式会社 | 癒着防止材 |
CN104546891A (zh) * | 2005-08-03 | 2015-04-29 | 塞尔索斯治疗公司 | 脂质结合物在囊性纤维化病中的用途及其应用 |
CN1771986A (zh) * | 2005-10-28 | 2006-05-17 | 凌沛学 | 口服关节功能保护剂 |
US20110130555A1 (en) | 2009-05-11 | 2011-06-02 | Saul Yedgar | Lipid-polymer conjugates, their preparation and uses thereof |
US8859524B2 (en) | 2005-11-17 | 2014-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of chronic rhinosinusitis |
US8906882B2 (en) | 2005-11-17 | 2014-12-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of allergic rhinitis |
US20080183282A1 (en) * | 2006-03-09 | 2008-07-31 | Saul Yedgar | Use of lipid conjugates for the coating of stents and catheters |
WO2008059502A2 (en) * | 2006-11-14 | 2008-05-22 | Yissum Research Development Company | Contact lens compositions |
CA2705785A1 (en) | 2006-11-14 | 2008-05-22 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases or disorders of the eye |
FR2908775B1 (fr) * | 2006-11-17 | 2012-08-31 | Biomatlante | Hydrogel et ses applications biomedicales |
CA2703532C (en) * | 2010-05-10 | 2018-05-01 | Eva Turley | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5122450A (en) * | 1985-10-24 | 1992-06-16 | Research Corporation Limited | Biochemical reagent |
GB2201919A (en) | 1987-02-07 | 1988-09-14 | David Barke | Computer stationery |
JP2953702B2 (ja) * | 1989-01-20 | 1999-09-27 | 生化学工業株式会社 | 合成コンドロイチン硫酸プロテオグリカンを含有する組織癒着防止剤 |
US5464942A (en) * | 1990-07-24 | 1995-11-07 | Seikagaku Kogyo Kabushiki Kaisha | Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same |
-
1992
- 1992-07-30 JP JP20355892A patent/JP3714683B2/ja not_active Expired - Fee Related
-
1993
- 1993-07-28 CA CA002101482A patent/CA2101482A1/en not_active Abandoned
- 1993-07-29 US US08/098,936 patent/US5470578A/en not_active Expired - Lifetime
- 1993-07-29 DE DE69324859T patent/DE69324859T2/de not_active Expired - Fee Related
- 1993-07-29 AT AT93112169T patent/ATE179892T1/de not_active IP Right Cessation
- 1993-07-29 EP EP93112169A patent/EP0581282B1/de not_active Expired - Lifetime
- 1993-07-30 KR KR1019930014655A patent/KR940005281A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR940005281A (ko) | 1994-03-21 |
DE69324859D1 (de) | 1999-06-17 |
US5470578A (en) | 1995-11-28 |
CA2101482A1 (en) | 1994-01-31 |
JPH0672893A (ja) | 1994-03-15 |
AU4431493A (en) | 1994-02-03 |
AU668963B2 (en) | 1996-05-23 |
ATE179892T1 (de) | 1999-05-15 |
JP3714683B2 (ja) | 2005-11-09 |
EP0581282B1 (de) | 1999-05-12 |
EP0581282A1 (de) | 1994-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69324859T2 (de) | Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis | |
MX9302932A (es) | Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa. | |
DE69130614D1 (de) | Herbizide, substituierte aryl-haloalkylpyrazole | |
HU9203074D0 (en) | 2-substituted indene-2-mercapto-acetamide being inhibitors of encefalinase and ace | |
DE69109560D1 (de) | Fungizide Zusammensetzung zur Behandlung von Saatgut. | |
DE122009000012I1 (de) | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen. | |
DE69224080T2 (de) | Verwendung von nsaid zur behandlung von demenz | |
DE69307509D1 (de) | Vorrichtung zur behandlung von herzfehlern | |
DE69214397D1 (de) | 2-Substituierte Indane-2-Carboxyalkyl-Verbindungen mit Enkephalinase und ACE-Hemmwirkung | |
NO912758D0 (no) | Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger. | |
IT8122675A0 (it) | Mercaptoacil derivati di varie proline 4 sostituite e relative composizioni utili per il trattamento dell'ipertensione. | |
DE69806579T2 (de) | Anlage zur behandlung von nahrungsmitteln | |
DK0705100T3 (da) | Terapeutiske substituerede guanidiner | |
DE68914292D1 (de) | Zusammensetzung zur Behandlung von ischämischen Störungen in Organen. | |
DE69401577D1 (de) | Verabreichung von lamotrigin zur behandlung von neuro-aids | |
MX9302931A (es) | Nuevas 4-aza-5&-colestan-onas 7b-substituidas como inhibidores de 5&-reductasa. | |
ES2191659T3 (es) | Derivados heterociclicos substituidos utiles como inhibidores de la agregacion plaquetaria. | |
ATE267180T1 (de) | Phosphorderivate zur behandlung von aids | |
DE69405919D1 (de) | Zusammensetzungen zur Behandlung von Keratinfasern | |
FI891813A (fi) | Mikro-organismeja tappava/mikro-organismien kasvua estävä koostumus teollista käyttöä varten sekä menetelmä mikro-organismien tappamiseksi tai niiden kasvun estämiseksi | |
DE59209268D1 (de) | Verfahren zur thermochemisch-thermischen behandlung von einsatzstählen | |
DE69431199T2 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen | |
DE69432626D1 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen | |
DE69112743D1 (de) | Anlage zur Behandlung von Tierexkrementen. | |
GR3034661T3 (en) | Use of Selegiline in vetenary medicine. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |